Benzene Ring Containing Patents (Class 514/107)
-
Publication number: 20120138506Abstract: The invention relates a pharmaceutical composition comprising a combination of (i) the AT 1-antagonist valsartan or a pharmaceutically acceptable salt thereof and (ii) a NEP inhibitor or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier and to a method for the treatment or prevention of selected conditions or diseases.Type: ApplicationFiled: December 16, 2011Publication date: June 7, 2012Inventors: Gary Michael Ksander, Randy Lee Webb
-
Publication number: 20120108549Abstract: Apocynin derivative compounds, active pharmaceutical ingredients, dosage forms, and methods of use thereof as neuroprotectants in the brain of mammals.Type: ApplicationFiled: April 15, 2010Publication date: May 3, 2012Inventors: Balaraman Kalyanaraman, Joy Joseph, Anumantha Kanthasamy
-
Publication number: 20120108548Abstract: This invention provides novel compositions to inhibit the aggregation of amyloid proteins. In various embodiments the compositions comprise a molecular tweezers that binds lysine and/or arginine and thereby inhibits the aggregation of amyloidogenic proteins.Type: ApplicationFiled: March 5, 2010Publication date: May 3, 2012Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, UNIVERSITÄT DUISBURG-ESSEN, MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Gal Bitan, Akila Shanmugam, Aleksey Lomakin, Thomas Schrader, Frank Gerrit Klarner, Peter Talbiersky, Jolanta Polkowska, Frank Bastkowski, Sharmistha Sinha, Sally Frautschy
-
Publication number: 20120101067Abstract: Described herein are methods for improving engraftment of hematopoietic cells in an individual following hematopoietic progenitor cell transplantation (e.g., via bone marrow or cord blood transplantation). Methods for increasing hematopoietic progenitor cell proliferation in individuals with bone marrow aplasia are also described. The methods involve administering an agent that inhibits adipogenesis, adipocyte growth, adipocyte differentiation and/or adipocyte proliferation.Type: ApplicationFiled: April 15, 2010Publication date: April 26, 2012Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Olaia Naveiras, George Daley, Pamela L. Wenzel
-
Patent number: 8153588Abstract: The invention relates to a combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor, said preparation being adapted for (a) the administration of parathyroid hormone during a period of approximately 6 to 24 months; (b) after the administration of parathyroid hormone has been terminated, the administration of a bone resorption inhibitor during a period of approximately 12 to 36 months.Type: GrantFiled: June 23, 2010Date of Patent: April 10, 2012Assignee: NPS Pharmaceuticals, Inc.Inventors: John Dietrich, Sverker Ljunghall, Sven Sjögren
-
Publication number: 20120064088Abstract: The present invention is directed to a method for treating aneurysms in vascular tissue. The method includes administering a bisphosphonate compound to a subject in an amount which is effective against the formation or progression of aneurysm, or which is effective to induce regression of an established aneurysm. In alternative methods, an anti-RANKL neutralizing antibody is administered to the subject to achieve analogous anti-aneurysm effect. The methods of particular advantage in the treatment of subjects having an abdominal aortic aneurysm, a relatively common, and life-threatening, condition.Type: ApplicationFiled: September 9, 2011Publication date: March 15, 2012Applicant: Wisconsin Alumni Research FoundationInventors: Dai Yamanouchi, K. Craig Kent, Bo Liu
-
Publication number: 20120058966Abstract: The invention relates to prodrugs of hydroxyl-substituted adamantane compounds, pharmaceutical compositions thereof, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.Type: ApplicationFiled: March 12, 2010Publication date: March 8, 2012Applicant: APOGEE BIOTECHNOLOGY CORPORATIONInventors: Charles D. Smith, Yan Zhuang, Lynn W. Maines
-
Publication number: 20120046247Abstract: This invention relates to compounds of Formula (I), (II), or (III) as shown in the specification, which contain a 1,5-diphenylpenta-1,4-dien-3-one backbone. These compounds can be used to treat cancer, inflammatory disease, or autoimmune disease.Type: ApplicationFiled: August 16, 2011Publication date: February 23, 2012Inventors: Charles C-Y Shih, Toshio Kitamura, Qian Shi, Toshiyuki Kawashima, Hui-Kang Wang
-
Publication number: 20120022024Abstract: This disclosure relates to compositions and methods including for the inhibition, prevention, and/or treatment of microbial infections, including infections from such pathogens as Staphylococcus aureus.Type: ApplicationFiled: July 21, 2011Publication date: January 26, 2012Applicant: The Board of Trustees of the University of IllinoisInventors: Eric Oldfield, Yongcheng Song
-
Publication number: 20110275581Abstract: A method of treating cancer in a subject comprising the step of administering to the subject in need thereof an effective amount of a combination of a compound that binds a nuclear export signal (NES inhibitor) on topoisomerase II? and a topoisomerase inhibitor. Twenty small molecule inhibitors (SMI) that bind to the two nuclear export sequences (NES) topo II? have been identified from the NCI database using computer-generated molecular modeling. These SMI will improve the effectiveness of topo II directed therapeutics, particularly in the treatment of diseases such as multiple myeloma (MM). In vitro apoptosis assays indicate that these drugs may be effective as single agents or in combination with currently used cancer drugs that target topo II.Type: ApplicationFiled: June 13, 2011Publication date: November 10, 2011Applicants: University of Florida Research Foundation, Inc., H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventors: Daniel M. Sullivan, Joel G. Turner, Thomas C. Rowe, David A. Ostrov
-
Publication number: 20110251158Abstract: Described herein are methods for treating inflammatory disorders or for inhibiting the build-up of arterial plaque. The methods comprise administering to a subject in need thereof a therapeutically effective amount of a synthetically modified fullerene.Type: ApplicationFiled: September 16, 2010Publication date: October 13, 2011Applicant: Luna Innovations IncorporatedInventors: Christopher L. KEPLEY, Robert P. LENK, Darren K. MACFARLAND, Zhiguo ZHOU
-
Publication number: 20110237551Abstract: The invention relates to the use of para-coumaric acid or para-hydroxycinnamic acid derivatives in cosmetic or dermatological compositions, specifically to the use of at least one compound derived from para-coumaric acid having a general formula (I) below: in which, especially, Z represents an oxygen or an —NH— group; X and Y are identical and each represent a CH or CH2 group, as an active principle with depigmenting, free-radical-scavenging and/or antiinflammatory is activity. The invention also relates to the use of the above compounds for cosmetic care or for the preparation of a pharmaceutical composition, especially for depigmenting an area of skin, having antiradical and/or antiinflammatory activity.Type: ApplicationFiled: June 3, 2011Publication date: September 29, 2011Applicants: BASF Beauty Care Solutions France S.A.S., Universite Joseph Fourier-Grenoble 1Inventors: Sabrina Okombi, Delphine Rival, Ahcene Boumendjel, Anne-Marie Mariotte, Eric Perrier
-
Publication number: 20110230447Abstract: Disclosed are: a compound which can be produced through a chemical synthesis at low cost, has an excellent osteogenesis-promoting activity, has high affinity for a bone, and can be applied without the need of any special DDS; and a method for promoting osteogenesis by administering the compound and applying the promotion of osteogenesis to the formation or regeneration of a bone. Specifically disclosed are: an osteogenesis promoter or a pharmaceutical composition comprising [4-(methylthio)phenylthio]methanebisphosphonic acid, which is one of bisphosphonic acids, or a pharmaceutically acceptable salt thereof as an active ingredient; and a method for promoting osteogenesis, which comprises administering the osteogenesis promoter or the pharmaceutical composition to a subject to be treated.Type: ApplicationFiled: August 5, 2009Publication date: September 22, 2011Applicants: Tohoku University, Showa UniversityInventors: Hisashi Shinoda, Kaoru Igarashi, Shinobu Murakami, Keiko Suzuki
-
Patent number: 7988950Abstract: The present invention relates to a novel class of paramagnetic ion-based contrast i agents of formula (I), wherein a chelating backbone moiety is highly functionalized by the presence of one or more polyhydroxylated chain, that show a pharmacokinetic i profile analogous to that of the commonly used T1-general extravascular agents (NSA) but are further characterized by a higher relaxivity.Type: GrantFiled: June 28, 2005Date of Patent: August 2, 2011Assignee: Bracco Imaging S.p.A.Inventors: Silvio Aime, Matteo Galli, Luciano Lattuada, Pierfrancesco Morosini, Fulvio Uggeri, Kondareddiar Ramalingam
-
Publication number: 20110112054Abstract: The present invention describes organophosphorus compounds of general formula (I) their preparation and their uses in the activation of gamma/delta T-cells, in the screening of GcpE and LytB enzyme inhibitors and in the prophylaxis and treatment of diseases in humans and animals.Type: ApplicationFiled: January 17, 2011Publication date: May 12, 2011Applicant: BIOAGENCY AGInventors: Hassan Jomaa, Matthias Eberl, Boran Altincicek, Martin Hintz, Oliver Wolf, Ann-Kristin Kollas, Armin Reichenberg, Jochen Wiesner
-
Publication number: 20110098252Abstract: The invention is directed to a method of treating chronic spinal mechanical pain by intravenous administration to a subject in need of chronic spinal mechanical pain relief of an effective amount of bisphosphonate.Type: ApplicationFiled: December 8, 2010Publication date: April 28, 2011Applicant: New York UniversityInventor: Marco Pappagallo
-
Publication number: 20100311695Abstract: The present invention relates to hydroxy-bisphosphonic acid derivatives corresponding to general formula (I): in which: -n and m denote, independently of one another, an integer ranging from 1 to 4, —X denotes an oxygen atom or an N—R3 group, —R1 and R3 denote, independently of one another, a linear or branched C1 to C6 alkyl group, and —R2 denotes a residue of a molecule of therapeutic or diagnostic interest, or pharmaceutically acceptable salts of said derivatives, and also the method for the preparation thereof and the therapeutic or diagnostic use thereof.Type: ApplicationFiled: January 5, 2009Publication date: December 9, 2010Inventors: Maxim Egorov, Yannick Fortun, Dominique Heymann, Jacques Lebreton, Monique Mathe, Marc Padrines, Francoise Redini
-
Patent number: 7838512Abstract: Methods and compositions for enhancing cancer cell death using therapeutically effective amounts of DNA damaging agent(s) that act in combination to enhance cancer cell death, e.g., nucleic acid precursors, and protein tyrosine kinase inhibitors, e.g., that inhibit EGFR activity. The agents and inhibitors are administered in an amount effective to kill cancer cells, that is, the combined effect is sufficient so that cancer cell death is enhanced. If not administered at the same time, the DNA damaging agent(s) and tyrosine kinase inhibitors are administered close enough in time so they are still able to enhance cancer cell death. The methods and compositions are useful to treat neoplastic disease, e.g., pancreatic cancer.Type: GrantFiled: May 2, 2006Date of Patent: November 23, 2010Assignees: Arch Development Corporation, Dana-Farber Cancer InstituteInventors: Donald Kufe, Ralph R. Weichselbaum
-
Publication number: 20100247640Abstract: The invention relates to a pharmaceutical composition and oral dosage forms comprising a bisphosphonate in combination with an enhancer to enhance intestinal delivery of the bisphosphonate to the underlying circulation. Preferably, the enhancer is a medium chain fatty acid or a medium chain fatty acid derivative having a carbon chain length of from 6 to 20 carbon atoms, and the solid oral dosage form is a controlled release dosage form such as a delayed release dosage form.Type: ApplicationFiled: April 26, 2010Publication date: September 30, 2010Inventor: Thomas W. Leonard
-
Publication number: 20100240612Abstract: The invention provides methods to treat a mycobacterium infection and methods to inhibit mycobacterial polyprenyl pyrophosphate synthesis with a compound of formula I. The invention also provides novel compounds of formula I as well as salts and prodrugs thereof.Type: ApplicationFiled: March 22, 2010Publication date: September 23, 2010Applicant: University of Iowa Research FoundationInventors: David F. Wiemer, Rocky J. Barney, Raymond J. Hohl
-
Publication number: 20100216747Abstract: An object of the present invention is to provide a preventive drug and a therapeutic drug for diseases caused by abnormal bone metabolism, especially osteoporosis, which is more effective than conventional drugs. Combined use of N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine, or a salt thereof; and at least one compound selected from the group consisting of etidronic acid, clodronic acid, pamidronic acid, tiludronic acid, risedronic acid, minodronic acid, ibandronic acid, zoledronic acid, and salts thereof can exert higher bone resorption inhibitory effect and provide a preventive effect and a therapeutic effect for diseases caused by abnormal bone metabolism, especially osteoporosis as compared with administration of the respective agents respectively.Type: ApplicationFiled: August 1, 2008Publication date: August 26, 2010Applicant: TEIJIN PHARMA LIMITEDInventors: Eiji Ochiai, Miyuki Nishiga, Kenichiro Takagi, Yoshiaki Azuma
-
Publication number: 20100173871Abstract: A method for treating inflammatory diseases through an anti-inflammatory type activation of monocytes, the method includes the administration to a patient in need thereof of an effective quantity of at least one dendrimer with mono- or biphosphonic terminations.Type: ApplicationFiled: August 1, 2008Publication date: July 8, 2010Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Mary Poupot, Remy Poupot, Jean-Jacques Fournie, Damien Portevin, Severine Fruchon, Jean-Luc Davignon, Cedric-Olivier Davignon, Anne-Marie Caminade, Jean-Pierre Majoral, Oliver Rolland
-
Patent number: 7749543Abstract: The invention relates to a combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor, said preparation being adapted for (a) the administration of parathyroid hormone during a period of approximately 6 to 24 months; (b) after the administration of parathyroid hormone has been terminated, the administration of a bone resorption inhibitor during a period of approximately 12 to 36 months.Type: GrantFiled: January 9, 2009Date of Patent: July 6, 2010Assignee: NPS Pharmaceuticals, Inc.Inventors: John Dietrich, Sverker Ljunghall, Sven Sjogren
-
Publication number: 20100144678Abstract: Small molecule bradykinin inhibitor bisphosphonate amide derivatives useful for inhibiting cancer growth and treating cancer residing in and around bone are disclosed. These compounds and pharmaceutical compositions containing these compounds are particularly useful for the treatment of prostate cancer bone metastases.Type: ApplicationFiled: April 9, 2008Publication date: June 10, 2010Applicant: The Regents of the University of colorado, a body corporateInventors: Lajos Gera, John M. Stewart, Leland W.K. Chung, Daqing Wu
-
Publication number: 20100056482Abstract: This invention relates to compounds having the following formula (I): of compositions including them, uses of these compounds, particularly for preparation of medicines, and in vitro induction processes for apoptosis and direct death of cancer cells.Type: ApplicationFiled: April 18, 2007Publication date: March 4, 2010Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS, UNIVERITE CLAUDE BERNARD - LYON 1Inventors: William Anthony Coleman, Loris Gilbert Baggetto, Adina Nicoleta Lazar, Mickael Henri Michaud, Sandrine Magnard
-
Publication number: 20100048511Abstract: Provided is a solid dispersion comprising vitamin D or a derivative thereof and a cyclodextrin; a complex formulation for the prevention or treatment of osteophorosis, which includes the solid dispersion and a bisphosphonate; and a method for preparing said complex formulation. The complex formulation can maintain a constant therapeutic level of vitamin D or a derivative thereof through its improved drug stability, while enhancing the patient compliance by minimizing inconvenience and adverse effects when administered to patients.Type: ApplicationFiled: November 6, 2007Publication date: February 25, 2010Applicant: HANMI PHARM CO., LTD.Inventors: Jong Soo Woo, Hong Gi Yi, Ju Nam Jin
-
Publication number: 20090247490Abstract: The present invention provides topical compositions containing phosphorylated polyphenols in combination with a topically acceptable carrier. The compositions of the invention provide a means for delayed delivery of the polyphenol to keratinous tissues, such as skin, hair and nails, with enzymes of the keratinous tissue dephosphorylating the polyphenol, and returning it to its native active form. The compositions are particularly useful in the regulation of skin conditions. the phosphorylated stilbene is a phosphorylated resveratrol or a phosphorylated resveratrol derivative.Type: ApplicationFiled: June 9, 2009Publication date: October 1, 2009Inventors: Lieve Declercq, Hugo Corstjens, Daniel Maes, Willy Van Brussel, Geert Schelkens
-
Publication number: 20090192098Abstract: This invention relates to methods for treating a hematopoietic neoplasm comprising administering a therapeutically effective amount of a combretastatin compound, or a pharmaceutically acceptable salt thereof, to a subject having a hematological malignancy, wherein the combretastatin compound comprises a catechol or quinone moiety and is capable of forming a reactive oxygen species (ROS) in vivo. The method may further comprise co-administering a second chemotherapeutic agent.Type: ApplicationFiled: November 21, 2008Publication date: July 30, 2009Applicant: OXIGENE, INC.Inventors: David Chaplin, Bronwyn G. Siim
-
Publication number: 20090156560Abstract: Disclosed herein are compounds that are tissue-nonspecific alkaline phosphatase inhibitors. The disclosed compounds are used to treat, prevent, or abate vascular calcification, arterial calcification and other cardiovascular diseases.Type: ApplicationFiled: May 8, 2008Publication date: June 18, 2009Inventors: JOSE LUIS MILLAN, EDUARD SERGIENKO
-
Patent number: 7547686Abstract: A new and more efficient synthesis of combretastatin A-3 (2a) was completed (8.4% overall yield) starting from methyl gallate and isovanillin with aldehyde 5 and phosphonium salt 8 as key intermediates. Conversion of combretastatin A-3 (2a) to a series of diphosphate prodrugs (lOa-lOl) containing selected anions was achieved. Both the diphosphate sodium (lOa) and potassium salts (lOc) displayed aqueous solubility in excess of 220 mg/ml at room temperature and good cancer cell line inhibitory activity.Type: GrantFiled: June 17, 2002Date of Patent: June 16, 2009Assignee: Arizona Board of Regents, a body corporate of the State of Arizona, Acting for and on Behalf of the Arizona State UniversityInventors: George R. Pettit, Mathew D. Minardi
-
Publication number: 20090099137Abstract: Compounds of the general formula are disclosed with activity towards treating diseases related to inflammation, such as cancer, neurodegenerative and cardiovascular diseases. Pharmaceutical compositions and methods of use are also described.Type: ApplicationFiled: August 11, 2008Publication date: April 16, 2009Inventor: Basil Rigas
-
Patent number: 7507715Abstract: The invention relates to a combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor, said preparation being adapted for (a) the administration of parathyroid hormone during a period of approximately 6 to 24 months; (b) after the administration of parathyroid hormone has been terminated, the administration of a bone resorption inhibitor during a period of approximately 12 to 36 months.Type: GrantFiled: December 19, 2005Date of Patent: March 24, 2009Assignee: NPS Allelix Corp.Inventors: John Dietrich, Sverker Ljunghall, Sven Sjogren
-
Publication number: 20090075943Abstract: Analogs of combretastatin have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin polymerization. Such compounds are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as pro-drugs, may well prove to be tumor selective vascular targeting chemotherapeutic agents or to have vascular targeting activity resulting in the selective prevention and/or destruction of nonmalignant proliferating vasculature.Type: ApplicationFiled: August 22, 2008Publication date: March 19, 2009Inventors: Kevin G. PINNEY, Madhavi Sriram
-
Publication number: 20090075861Abstract: Systems and methods remove and manage heavy metals. In one implementation, an exemplary method can be applied to food processing and food consumption to remove heavy metals such as mercury, lead, uranium and cadmium before absorption by a living organism. The exemplary method exposes the food to a heavy-metal binding ligand, such as a concentrated protein or phytic acid, to form a heavy-metal chelate, and then allows the chelate to separate from the food. In another implementation, an exemplary probe possesses innovative molecular layers on its surface to detect and quantify heavy metals by attracting and binding traces of the heavy metals on a ligand layer.Type: ApplicationFiled: June 6, 2008Publication date: March 19, 2009Inventor: ANNE SCHWARTZ
-
Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And An Oil Phase Structuring Agent
Publication number: 20090035236Abstract: An emulsion cosmetic composition comprising at least one resveratrol derivative, an aqueous phase, and an oil phase having at and at least one oil phase structuring agent, and a method for preparing emulsions capable of delivering active resveratrol to the skin.Type: ApplicationFiled: May 27, 2008Publication date: February 5, 2009Inventors: Daniel H. Maes, Fatemeh Mohammadi, Lisa Qu, Anna Czarnota, Thomas Wammone, Lieve Declercq, Julius R. Zecchino -
Publication number: 20080311189Abstract: The invention provides several molybdenum (II) complexes (see classes I and II, FIG. 1) as well as pharmaceutical compositions comprising these compounds, that are useful for treating cancer and describes synthetic methods and intermediates useful for preparing the compounds.Type: ApplicationFiled: March 18, 2004Publication date: December 18, 2008Inventors: Marta R.P. Norton Matos, Carlos C. Romao, Claudia Cristina Lage Pereira, Sandra S. Rodrigues, Marcia Mora, Maria Joao Pires Silva, Paula M. Alves, Celso Albuquerque Reis
-
Patent number: 7166584Abstract: Methods and compounds are disclosed for lowering serum LDL levels or serum cholesterol levels, or for reducing the transport of cholesterol from the gut to the blood or the lymph, based on the observation that a gene known as ABC1 is necessary in order for cholesterol to be transported from the intestinal lumen into the bloodstream. A mutant chicken phenotype, known as the WHAM chicken, characterized by low levels of serum LDL and reduced transport of cholesterol, facilitated the discovery of this function of the ABC1 gene. Techniques which act to inhibit ABC1 activity in the cells of the intestinal wall will result in lower serum cholesterol.Type: GrantFiled: November 1, 2000Date of Patent: January 23, 2007Assignees: Wisconsin Alumni Research Foundation, Xenon Genetics, Inc.Inventors: Alan D. Attie, Mark Cook, Mark P. Gray-Keller, Michael R. Hayden, Simon Pimstone, Angela R. Brooks-Wilson
-
Patent number: 7138388Abstract: This invention provides methods for treating inflammatory or autoimmune diseases by contacting the affected cell or tissue with a therapeutic compound as described herein. Such pathologies include, but are not limited to rheumatoid arthritis, systemic lupus erythmatosus, psoriatic arthritis, reactive arthritis, Crohn's disease, ulcerative colitis and scleroderma. Therapeutic compounds useful in the methods of this invention are selected from the group consisting of a 1,5-substituted pyrimidine derivative or analog and substituted furano-pyrimidone analog.Type: GrantFiled: January 18, 2002Date of Patent: November 21, 2006Assignee: Celmed Oncology (USA), Inc.Inventor: H. Michael Shepard
-
Patent number: 7078393Abstract: In a method for preparing 1-hydroxy-1,1-diphosphonic acid compounds of the general formula I and/or of their pharmacologically compatible salts a compound of the formula II is reacted with a compound P(OSiR53)3-pR6p and the reaction product is hydrolyzed.Type: GrantFiled: March 12, 2002Date of Patent: July 18, 2006Assignee: EUCRO European Contract Research GmbH & Co. KGInventors: Helmut Blum, Wolfgang Greb, Yurii Pustovit, Gerd-Volker Röschenthaler
-
Patent number: 7078059Abstract: The invention provides a method for enhancing bone formation, inhibiting osteoclastic differentiation and/or activating osteoblastic differentiation whereby to manage, treat or achieve prophylaxis of bone disease which comprises administering to a human or animal subject suffering from, or susceptible to bone disease a therapeutically or prophylactically effective amount of a lanthanum compound.Type: GrantFiled: June 26, 2001Date of Patent: July 18, 2006Assignee: Shire Holdings AGInventors: Nigel D. Atherton, Joseph William Totten, Michael David Gaitonde
-
Patent number: 7071232Abstract: The present invention relates to peptide-like compounds, e.g. aminocarboxylic acid amide derivatives, and to methods of using same in the field of general health care, for example, to improve resistance to stress, improve production of desired characteristics or useful products in animals, to increase weight gain, prevent diseases caused by pathogens, and to decrease feed efficiency. The invention has applications in the field of animal husbandry, and in treating or preventing weight loss associated with a disease in humans. It also relates to administering carbobenzoxy beta-alanyl taurine to improve feed efficiency in an animal, comprising administering to the animal an amount of carbobenzoxy beta-alanyl taurine sufficient to reduce the amount of food required to increase a unit of weight in the animal.Type: GrantFiled: August 14, 2000Date of Patent: July 4, 2006Inventor: Floyd E. Taub
-
Patent number: 7018982Abstract: The invention relates to a combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor, said preparation being adapted for (a) the administration of parathyroid hormone during a period of approximately 6 to 24 months; (b) after the administration of parathyroid hormone has been terminated, the administration of a bone resorption inhibitor during a period of approximately 12 to 36 months.Type: GrantFiled: March 18, 2003Date of Patent: March 28, 2006Assignee: NPS Allelix Corp.Inventors: John Dietrich, Sverker Ljunghall, Sven Sjögren
-
Patent number: 6896871Abstract: The present invention is directed to particular bisphosphonate compounds, and in particular, to bisphosphonate conjugates that are useful in the treatment of soft tissues surrounding bone and bone-related diseases, such as bone cancer and osteoporosis.Type: GrantFiled: April 10, 2001Date of Patent: May 24, 2005Assignee: MBC Research, Inc.Inventors: Alexander Karpeisky, Nelly Padioukova, Sergey Mikhailov, H.B.F. Dixon, Grigorii Tzeitline, Marat Karpeisky
-
Patent number: 6835722Abstract: The present invention relates to a pharmaceutical composition for the treatment of metabolic bone disease and the method of preparation thereof, and more particularly, to an improved pharmaceutical composition for the therapeutic treatment of metabolic disease and the method of preparation thereof, wherein said composition is prepared as a composite pharmaceutical agent which comprises calcitriol; which reduces the rate of spine fractures and increases bone density; alendronate, a bone resorption inhibitor, as two main active ingredients in an optimal mixing ratio to exert the greatest synergistic therapeutic effect; and adequate amount of other additives such as a resorption fortifier of alendronate.Type: GrantFiled: April 19, 2002Date of Patent: December 28, 2004Assignee: Yuyu Industrial Co., Ltd.Inventors: Sung An Kang, Kyung Hee Lee, Chung Shil Kwak, Chang Jong Kim, Yong Oh Lee
-
Patent number: 6787528Abstract: The compounds of formula (I) are hydrophilic aryl phosphate, thiophosphate, and aminophosphate intestinal apical membrane Na-mediated phosphate co-transportation inhibitors. The compounds can be administered orally, where they act to inhibit Na-dependent phosphate uptake in the intestines, or internally, where they interact with the phosphate control functions of the kidneys and parathyroid. They are therefore useful for inhibiting sodium-mediated phosphate uptake, reducing serum PTH, calcium, calcitriol, and phosphate, and treating renal disease in an animal, including a human.Type: GrantFiled: January 7, 2002Date of Patent: September 7, 2004Assignee: Board of Regents, The University of Texas SystemInventor: Brian E. Peerce
-
Patent number: 6784168Abstract: A synergistic biocide comprises a tris(hydroxymethyl)phosphine or a tetrakis (hydroxymethyl)phosphonium salt and at least one non-surfactant biopenetrant, such as a polymer or copolymer having a plurality of quaternary ammonium groups, a hydrotrope or a syntan, together optionally with a surfactant.Type: GrantFiled: September 5, 2000Date of Patent: August 31, 2004Assignee: Rhodia Consumer Specialties LimitedInventors: Christopher Raymond Jones, Robert Eric Talbot
-
Patent number: 6750340Abstract: The present invention is directed to particular bisphosphonate compounds, and in particular, to bisphosphonate conjugates that are useful in the treatment of soft tissues surrounding bone and bone-related diseases, such as bone cancer and osteoporosis.Type: GrantFiled: December 7, 2000Date of Patent: June 15, 2004Assignee: MBC Research, Inc.Inventors: Nelly Padioukova, Sergey Mikhailov, H. B. F. Dixon, Grigorii Tzeitline
-
Patent number: 6699850Abstract: The present invention relates to oral compositions and methods for inhibiting bone resoprtion in a mammal while counteracting the occurrence of potentially adverse gastrointestinal effects. The compositions useful herein comprise the combination of a pharmaceutically effective amount of a nitrogen-containing bisphosphonate or a pharmaceutically-acceptable salt thereof and a pharmaceutically effective amount of an isoprenoid compound.Type: GrantFiled: December 21, 2001Date of Patent: March 2, 2004Assignee: Merck & Co., Inc.Inventors: Alfred A. Reszka, Edward S. Scolnick
-
Patent number: 6680307Abstract: The invention relates to use of ibandronic acid (1-hydroxy-3-(N-methyl-N-pentyl)aminopropyl-1,1-diphosphonic acid) or physiologically compatible salts or esters thereof for improving the osseointegration of cement-free anchored endoprostheses. Ibandronate or salts thereof is applied for a short time immediately after insertion of an endoprosthesis, with the surprising result that secondary stability of the implant is obtained in only 5 weeks or less after the operation.Type: GrantFiled: May 31, 2001Date of Patent: January 20, 2004Assignee: Roche Diagnostics GmbHInventors: Frieder Bauss, Andreas A. Kurth
-
Patent number: 6677320Abstract: The present invention relates to a parenteral composition comprising a bisphosphonic acid or a pharmaceutically acceptable salt thereof (bisphosphonate) as active component and a pharmaceutically acceptable chelating agent, processes of the preparation of this composition, and methods of their use in the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, hypercalcemia of malignancy, and metabolic bone disease. The compositions are especially useful for improving the local tolerance of the active component when administered parenterally.Type: GrantFiled: January 11, 2001Date of Patent: January 13, 2004Assignee: Hoffmann-La Roches Inc.Inventors: Anke Diederich, Pierre Goldbach, Thomas Pfister